Genertec Universal Medical Group Company Limited
UMTAF
Other OTC0.60
USD
+0.05
- -
Genertec Universal Medical Group Company Limited
UMTAF
(Other OTC)
Recent
price
0.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genertec Universal Medical Group Company Limited (HK:2666; OTC:UMTAF), a subsidiary of China General Technology (Group) Holding Co., Ltd., engages in financing, advisory, and medical services in the People's Republic of China. Founded in 1984 and headquartered at No. 90 Side Road of West Third Ring Middle Road in Beijing, the company operates through two primary segments: Finance Business, which provides direct finance leasing, sale-and-leaseback arrangements, factoring, operating leases, and advisory services; and Healthcare Business, which encompasses medical and healthcare services, hospital operations and management, import/export and domestic trading of medical-related goods, equipment life cycle management, medical digitalization and technology services, intelligent medical health and elder care, hospital construction, medical consulting, and software development. It serves patients, hospitals, medical equipment suppliers, and public institutions primarily in mainland China, with some activities in Hong Kong, and manages a network of hospitals across regions including Huabei, Huadong, Huazhong, Dongbei, Xibei, and Xinan. In March 2025, the company collaborated with Industrial and Commercial Bank of China (ICBC) to launch Beijing's first "Specialized, Sophisticated, Special and New" M&A loan for technology-based enterprises, financing 80% of an acquisition transaction over a 10-year term to bolster hospital operations, medical equipment management, and intelligent elder care; it also established a joint venture company as announced in November 2025, alongside board changes including a non-executive director resignation and appointments to committees.